Health-related Quality of Life in Systemic Sclerosis Before and After Autologous Haematopoietic Stem Cell Transplant-a Systematic Review
Overview
Authors
Affiliations
Objectives: In severe rapidly progressive SSc, autologous haematopoietic stem cell transplantation (AHSCT) allows significant improvements in overall and event-free survival. We undertook this study to identify, appraise and synthesize the evidence on health-related quality of life (HRQoL) before and after AHSCT for SSc.
Methods: We performed a systematic review of the literature, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, in PubMed and ScienceDirect from database inception to 1 February 2019. All articles with original HRQoL data were selected.
Results: The search identified 1080 articles, of which 8 were selected: 3 unblinded randomized controlled trials [American Scleroderma Stem Cell versus Immune Suppression Trial (ASSIST), Autologous Stem Cell Transplantation International Scleroderma, Scleroderma: Cyclophosphamide or Transplantation), 3 uncontrolled phase I or II trials and 2 cohort studies. HRQoL data from 289 SSc patients treated with AHSCT and 125 treated with intravenous CYC as a comparator with median 1.25-4.5 years follow-up were included. HRQoL was evaluated with the HAQ Disability Index (HAQ-DI; 275 patients), the 36-item Short Form Health Survey (SF-36; 249 patients) and the European Quality of Life 5-Dimensions questionnaire (EQ-5D; 138 patients). The quality of the studies was moderate to low. AHSCT was associated with significant improvement in the HAQ-DI (P = 0.02-<0.001), SF-36 Physical Component Summary score (P = 0.02-<0.0001) and EQ-5D index-based utility score (P < 0.001). The SF-36 Mental Component Summary score improved in the ASSIST (n = 19) and one small retrospective cohort (n = 30 patients, P = 0.005) but did not improve significantly in 2 randomized controlled trials (n = 200 patients, P = 0.1-0.91).
Conclusion: AHSCT in severe SSc patients is associated with significant and durable improvement in physical HRQoL.
Schmalzing M, Gernert M, Frohlich M, Henes J, Schwindl N, Zerhusen L Front Immunol. 2024; 15:1436639.
PMID: 39512343 PMC: 11540678. DOI: 10.3389/fimmu.2024.1436639.
Stem cell-based therapy for systemic sclerosis.
Moghaddam M, Mousavi M, Ghotloo S Rheumatol Adv Pract. 2023; 7(3):rkad101.
PMID: 38075180 PMC: 10701795. DOI: 10.1093/rap/rkad101.
Hematopoietic Cell Transplantation for Systemic Sclerosis-A Review.
Levin D, Osman M, Durand C, Kim H, Hemmati I, Jamani K Cells. 2022; 11(23).
PMID: 36497169 PMC: 9739132. DOI: 10.3390/cells11233912.
Improving outcomes in scleroderma: recent progress of cell-based therapies.
Khanna D, Krieger N, Sullivan K Rheumatology (Oxford). 2022; 62(6):2060-2069.
PMID: 36355455 PMC: 10234204. DOI: 10.1093/rheumatology/keac628.
Trieste L, Cannizzo S, Palla I, Triulzi I, Turchetti G Front Med (Lausanne). 2022; 9:986218.
PMID: 36213631 PMC: 9537631. DOI: 10.3389/fmed.2022.986218.